Key Takeaways:

  • Largest-ever study of GLP-1 drugs in Type 1 diabetes shows 15% reduction in heart disease risk and 19% reduction in kidney failure
  • Analysis of 175,000 patients found no increased safety risks, contradicting earlier concerns about hypoglycemia and ketoacidosis
  • Results suggest Type 1 patients may benefit from GLP-1 treatments similarly to Type 2 patients, potentially expanding access

Major Study Changes Type 1 Diabetes Treatment Landscape

A landmark study from Johns Hopkins Bloomberg School of Public Health has delivered significant news for people with Type 1 diabetes: GLP-1 drugs significantly reduce the risk of major cardiovascular events and kidney disease without increasing safety concerns.

The massive analysis, published in Nature Medicine in March 2026, examined electronic health records from about 175,000 Type 1 diabetes patients across the U.S. — making it the largest study of its kind. Patients taking GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) saw their five-year risk of major cardiovascular events reduced by 15% and end-stage kidney disease reduced by 19%.

The findings are particularly significant because there have been few GLP-1 clinical trials measuring these outcomes in Type 1 patients, while landmark trials have shown roughly 20% risk reductions for Type 2 diabetes patients.

Why This Study Matters for Type 1 Patients

Type 1 diabetes affects about 2 million Americans, including 314,000 children and adolescents, according to the CDC. Unlike Type 2 diabetes, Type 1 is an autoimmune condition where the pancreas produces little to no insulin, requiring lifelong insulin therapy.

People with Type 1 diabetes face high lifetime risks of cardiovascular and kidney disease, as chronic excess blood sugar promotes atherosclerosis leading to heart attacks and strokes, while elevated blood sugar damages the kidney's filtering structures.

The Johns Hopkins researchers used a sophisticated "sequential target trial emulation" design to mimic clinical trial conditions while analyzing real-world data. The results showed the average five-year cardiovascular event risk dropped from 5.0% to 4.3%, with additional benefits including a 21% reduction in heart attacks and 16% reduction in all-cause mortality.

Safety Concerns Prove Unfounded

One of the study's most important findings addresses longstanding safety concerns. Earlier small trials had suggested GLP-1 drugs combined with insulin might increase risks of dangerous low blood sugar (hypoglycemia) or diabetic ketoacidosis.

Instead, the Hopkins study found estimated risks of hospitalization for hypoglycemia and diabetic ketoacidosis were significantly lower — 18% and 17% respectively — in patients taking GLP-1 drugs. Researchers concluded this suggests physicians are being careful when selecting patients and that patients are adjusting insulin doses appropriately.

"These risk reductions for heart and kidney disease outcomes are comparable to what we've seen for type 2 diabetes patients taking GLP-1-RA drugs, and it's reassuring that we saw no sign of any new safety issues," said study senior author Jung-Im Shin, MD, PhD.

Additional Benefits Beyond Heart and Kidney Protection

The study revealed several other significant benefits for Type 1 patients taking GLP-1 medications:

  • 18% reduction in heart failure risk and 28% reduction in major liver events
  • 22% higher likelihood of achieving at least 10% weight loss over five years

These findings are particularly relevant because weight management can be challenging for Type 1 patients, who often experience weight gain with intensive insulin therapy.

Understanding the Financial Picture

For many Type 1 patients interested in these potential benefits, understanding the costs involved is crucial. GLP-1 medication costs can vary significantly based on insurance coverage, with monthly prices ranging from under $100 with good insurance to over $1,000 without coverage. Since these drugs aren't yet FDA-approved specifically for Type 1 diabetes, insurance coverage may require prior authorization or appeals.

Many patients have found success working with specialized providers who understand the insurance approval process and can help navigate coverage options for off-label use in Type 1 diabetes.

What This Means for You

If you have Type 1 diabetes, this research represents the strongest evidence yet that GLP-1 medications could offer significant protection against the long-term complications that affect most people with your condition. While GLP-1 drugs aren't yet FDA-approved specifically for Type 1 diabetes, many endocrinologists are already prescribing them off-label for weight management and blood sugar control.

The key is finding healthcare providers experienced with using these medications in Type 1 patients, as the dosing and insulin adjustments require specialized knowledge. You can find clinics specializing in GLP-1 treatments through our directory, many of which have endocrinologists familiar with Type 1 applications. When discussing specific medications like semaglutide or tirzepatide with your doctor, this Hopkins study provides compelling evidence for the potential benefits.

While the researchers note that "ultimately large clinical trials are needed to confirm these findings," the massive scale and rigorous methodology of this observational study provide the best available evidence for GLP-1 benefits in Type 1 diabetes.

Sources

  1. Improved Heart and Kidney Outcomes for Type 1 Diabetes Patients Taking GLP-1 Weight Loss Drugs - Johns Hopkins Bloomberg School of Public Health press release, March 31, 2026
  2. Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes - Nature Medicine study publication, March 19, 2026